2 days ago · Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

1 day ago · The FDA approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic to treat moderate to severe acute pain in adults.

All News Consumer Pro New Drugs Pipeline Clinical Trials FDA Alerts FDA Approves Journavx FDA Approves Journavx (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain BOSTON-- (BUSINESS WIRE)--Jan. 30, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved Journavx ™ (suzetrigine ...

1 day ago · A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.

1 day ago · BOSTON, January 30, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non ...

1 day ago · Journavx works to treat pain by inhibiting the transmission of pain signals to the spinal cord and brain. FDA approval of Journavx was supported by data from two randomized, double-blind, placebo and active-controlled trials of acute pain: Trial 1 (following full abdominoplasty) and Trial 2 (following bunionectomy).

1 day ago · The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive.

1 day ago · WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical ...

1 day ago · Journavx (suzetrigine) is a new non-opioid pain-relieving tablet used to treat short-term moderate to severe pain. includes Journavx side effects, uses, interactions, and more.

20 hours ago · The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults. The active ingredient in Journavx is suzetrigine, a ...